Literature DB >> 12687850

Circadian rhythm of the corrected QT interval: impact of different heart rate correction models.

Peter Smetana1, Velislav Batchvarov, Katerina Hnatkova, A John Camm, Marek Malik.   

Abstract

A reduced circadian pattern in the QTc interval has been repeatedly reported to provide prognostic information in cardiac patients. However, the results of studies in healthy subjects in which different heart rate correction formulas were used are inconsistent regarding the presence and extent of diurnal variations in QTc. This study compared the diurnal variations in QTc obtained with four frequently used heart rate correction models with those based on individually optimized heart rate correction. In 53 subjects (25 men aged 27 +/- 7 years and 28 women aged 27 +/- 9 years) 12-lead digital ECGs were obtained every 30 seconds during 24 hours. The QT interval was measured automatically by six different algorithms provided by a commercially available device. The QT/RR relation was estimated by four common heart rate correction models and by an individually optimized correction model, QTc = QT/RR alpha. In each 24-hour recording, RR, QT, and WTc intervals of separate ECG samples were averaged over 10-minute intervals. Marked differences were found in the extent of the circadian pattern of QTc obtained with different formulas for heart rate correction. Under and overcorrection of the QT interval resulted in significant over- or underestimation of the circadian pattern. Thus, the extent of circadian variation in QTc depends highly on the heart rate correction formula used. To obtain proper insight regarding diurnal variation in QTc prolongation during pharmacologic therapy and/or to assess higher risk due to impaired autonomic regulation of ventricular repolarization, individualized heart rate correction is necessary.

Entities:  

Mesh:

Year:  2003        PMID: 12687850     DOI: 10.1046/j.1460-9592.2003.00054.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  15 in total

Review 1.  Assessing QT interval prolongation and its associated risks with antipsychotics.

Authors:  Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

2.  Choice of baseline in parallel thorough QT studies.

Authors:  Claus Graff
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

Review 3.  Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.

Authors:  Vladimir Piotrovsky
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

4.  Moxifloxacin versus placebo modeling of the QT interval.

Authors:  Philippe Grosjean; Saïk Urien
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-02-17       Impact factor: 2.745

Review 5.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

6.  QT intervals and QT dispersion determined from a 12-lead 24-hour Holter recording in patients with coronary artery disease and patients with heart failure.

Authors:  Stig Hansen; Verner Rasmussen; Christian Torp-Pedersen; Gorm Boje Jensen
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-01       Impact factor: 1.468

7.  Translating QT interval prolongation from conscious dogs to humans.

Authors:  Vincent F S Dubois; Giovanni Smania; Huixin Yu; Ramona Graf; Anne S Y Chain; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2016-10-29       Impact factor: 4.335

Review 8.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

9.  How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology - model-based case study.

Authors:  Barbara Wiśniowska; Zofia M Bielecka; Sebastian Polak
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-03-05       Impact factor: 2.745

10.  Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model.

Authors:  Y Huh; M M Hutmacher
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.